An increasing frequency of hepatic granulomas, up to 10%, in chronic hepatitis C patients is reported, and their presence is considered to be a predictor of treatment success. However, there is only one prevalence study on granuloma in chronic hepatitis B, and its significance for treatment outcome is unknown. We aimed to determine the prevalence of hepatic granulomas in a larger group of chronic hepatitis B patients and to compare their presence with the response to interferon therapy. Biopsy specimens of chronic hepatitis B patients were reevaluated for the presence of hepatic granulomas. All patients with hepatic granuloma were screened for other granulomatous diseases by tuberculin skin test, chest X-ray and computed tomography, venereal disease research laboratory, Brucella agglutination tests, and exposure to hepatotoxic agents. We screened 663 cases of chronic hepatitis B. Hepatic granulomas were found in 10 cases (1.5%). The granulomas could not be ascribed to any other reason. Of the 10 patients with hepatic granulomas, 4 responded to interferon therapy, 2 dropped out, and 4 were nonresponders. We conclude that hepatic granuloma is a rare finding in chronic hepatitis B and its presence does not seem to predict the response to interferon therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1023/b:ddas.0000043366.18578.15DOI Listing

Publication Analysis

Top Keywords

chronic hepatitis
28
hepatic granulomas
24
hepatitis patients
12
interferon therapy
12
prevalence hepatic
8
response interferon
8
patients hepatic
8
hepatic granuloma
8
granulomas
7
chronic
7

Similar Publications

Background: Conflicting results have been reported on the impact of tenofovir versus entecavir on liver-related outcomes.

Aims: To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)-infected patients and compare the impact of tenofovir versus entecavir on the risk of hepatocellular carcinoma (HCC), liver transplantation (LT) and mortality.

Methods: We used the French National Health Insurance Databases (SNDS) to identify HBV-infected patients.

View Article and Find Full Text PDF

The effect and application of adiponectin in hepatic fibrosis.

Gastroenterol Rep (Oxf)

December 2024

Department of Laboratory Medicine, First Hospital of Jilin University, Changchun, Jilin, P. R. China.

Hepatic fibrosis, a degenerative liver lesion, significantly contributes to the deterioration and mortality among patients with chronic liver diseases. The condition arises from various factors including toxins, such as alcohol, infections like different types of viral hepatitis, and metabolic diseases. Currently, there are no effective treatments available for liver fibrosis.

View Article and Find Full Text PDF

Hepatic encephalopathy (HE) is a clinical syndrome that can result from acute and chronic liver disorders, such as hepatitis, liver failure caused by alcohol or drugs, autoimmune diseases, metabolic diseases, cirrhosis, different types of tumors, and infections. This study aimed to investigate the effects of different doses of Beta-myrcene (β-myrcene) on the improvement of HE caused by thioacetamide (TAC) in male rats. To induce liver failure and acute damage in the studied animals, TAC was administered to rats at a dose of 100 mg/kg of body weight through an intraperitoneal (IP) injection with 24-hour intervals for seven consecutive days.

View Article and Find Full Text PDF

Dr. Jekyll or Mr. Hyde: The multifaceted roles of miR-145-5p in human health and disease.

Noncoding RNA Res

April 2025

Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, 11200 SW 8th Street, Miami, FL 33199, USA.

MicroRNAs (miRNAs) are classified as small, non-coding RNAs that play crucial roles in diverse biological processes, including cellular development, differentiation, growth, and metabolism. MiRNAs regulate gene expression by recognizing complementary sequences within messenger RNA (mRNA) molecules. Recent studies have revealed that miR-145-5p functions as a tumor suppressor in several cancers, including lung, liver, and breast cancers.

View Article and Find Full Text PDF

Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults.

BMC Med

December 2024

Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, 100191, China.

Background: Risk prediction models can identify individuals at high risk of chronic liver disease (CLD), but there is limited evidence on the performance of various models in diverse populations. We aimed to systematically review CLD prediction models, meta-analyze their performance, and externally validate them in 0.5 million Chinese adults in the China Kadoorie Biobank (CKB).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!